Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. [electronic resource]
Producer: 20160920Description: e464-73 p. digitalISSN:- 2352-3018
- Absorptiometry, Photon
- Adult
- Anti-HIV Agents -- administration & dosage
- Biomarkers -- blood
- Bone Density -- drug effects
- Bone Diseases, Metabolic -- chemically induced
- CD4 Lymphocyte Count
- Comorbidity
- Darunavir -- administration & dosage
- Drug Therapy, Combination
- Emtricitabine -- administration & dosage
- Europe -- epidemiology
- Female
- HIV Infections -- complications
- Humans
- Inflammation -- physiopathology
- Male
- Middle Aged
- Osteopetrosis -- chemically induced
- Raltegravir Potassium -- administration & dosage
- Ritonavir -- administration & dosage
- Tenofovir -- administration & dosage
- Viral Load
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.